Genmab — April 2017
-
God morgen.
-
royal..Jeg er 59 år. Forventer at være erhvervsaktiv resten af mit liv. Derfor er jeg generelt stadig meget langsigtet.
-
E L
-
Lyder som et spændende emne, jeg er 58 og har også svært ved at se hvordan jeg bedst muligt får nytte af pengene på bedst mulig måde
-
Ja og staten
-
Skattevæsenet får en ordentlig indsprøjtning hvis Genmab bliver solgt
-
-
Fandt lige dette gamle udsag: “We presented sensational data from tisotumab vedotin at ASCO last year, but no one really noticed them because Darzalex took all the attention. The market has a tendency to only focus on one thing at a time,” says Jan van de Winkel.
-
Genmab accelerates research efforts
Genmab will need to identify its next winning ticket in the coming three to four years, and its CEO is fully convinced that the drug is already hiding in the biotech company’s pipeline. The firm is now increasing its R&D budget in a bid to identify the winner.
(medwatch.dk)
-
@Helge (og andre), læste den forholdsvis komplekse forklaring på PD-1/PD-L1 virkningsmekanismen, og kunne se det beskrevet ift forsøg, at det forventes også at kunne ramme metastaser i hjernen. Som jeg forstår det ift PD-1, sker påvirkningen i nærmiljøet omkring kræftcellerne ved at hæmme PD-1. Det må betyde, at PD-1 hæmmere skal passere BBB (Blood-Brain-Barrier) for at påvirke metastaser i hjernen. Det ser ud til, at T-lymfocytter godt kan passere BBB, men jeg mangler lidt viden om Daras
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind